Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
IV vehicle risk is separate from oral renal dosing. Historical interactions and hepatic-study limits require exact current-label review; the preserved text is not an interaction-checking algorithm.
Check source scope before reading a dose
UCSF: voriconazole renal dosing and short-course IV caveat
Product / population
UCSF adult treatment and hematology/BMT prophylaxis; dosing update identified by the page as February 2025.
Renal method
Renal impairment, high-flux intermittent HD and the institution's stated CVVHD assumptions.
Source revision
Dosing updated February 2025 as stated on page.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
IV vehicle warning versus qualified institutional short-course use
VFEND favors oral therapy below its renal threshold unless an individualized benefit-risk assessment justifies IV use. UCSF acknowledges that warning and discusses limited evidence for short IV courses in selected patients. The guidance differs in emphasis, not through removal of the vehicle warning.
What to reconcile: Check the exact IV product and excipient, oral feasibility, intended duration, creatinine trend, interactions and drug-level monitoring. Neither source supports ignoring renal deterioration or automatically reducing the oral dose.
UCSF Infectious Diseases Management Program · UCSF adult treatment and hematology/BMT prophylaxis; dosing update identified by the page as February 2025.
Renal method: Renal impairment, high-flux intermittent HD and the institution's stated CVVHD assumptions. Source date: Dosing updated February 2025 as stated on page. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
UCSF lists no renal or hemodialysis dose adjustment. Its treatment schedule is 6 mg/kg IV/orally every twelve hours for two doses, then 4 mg/kg every twelve hours; hematology/BMT prophylaxis is 200 mg every twelve hours with a separate obesity caveat. Use total body weight unless over 120% of ideal weight, when adjusted weight is specified. The page acknowledges the manufacturer's IV-vehicle concern but cites limited evidence supporting short IV courses in selected patients with baseline impairment. This is a qualified benefit-risk perspective, not unrestricted permission to use IV therapy. The institutional dialysis assumptions are high-flux intermittent HD and CVVHD with 2 L/hour ultrafiltration plus residual native GFR. Review interacting drugs and therapeutic monitoring.
RDM40-professional-voriconazole-8bfbc51bc9-C1 · Source locator: Adult and HD tables, dosing weight rule, IV vehicle footnote and general considerations
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.